{"nctId":"NCT04693637","briefTitle":"Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant","startDateStruct":{"date":"2021-01-15","type":"ACTUAL"},"conditions":["Adenovirus Infection","BK Virus Infection","Cytomegalovirus Infections","Epstein-Barr Virus Infections","Human Herpes Virus-6 Infection","JC Virus Infection"],"count":26,"armGroups":[{"label":"Posoleucel (ALVR105)","type":"EXPERIMENTAL","interventionNames":["Biological: Posoleucel (ALVR105)"]}],"interventions":[{"name":"Posoleucel (ALVR105)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria\n\n* â‰¥1 year of age at the day of screening visit.\n* Either no evidence of viral infection or viremia, or asymptomatic, viral infection with 3 or fewer viruses of interest at time of screening\n* Within 15 and 42 days of receiving a first allogeneic HCT and have demonstrated clinical engraftment\n* Meet one or more of the following criteria at the time of randomization:\n\n  * Related (sibling) donor with at least one mismatch at one of these HLA-gene loci: HLA-A, -B or -DR\n  * Haploidentical donor\n  * Unrelated donor with at least one mismatch at one of these HLA-gene loci: HLA-A, -B, -C, or -DR\n  * Use of umbilical cord blood as stem cell source\n  * Ex vivo graft manipulation resulting in T cell depletion\n  * Lymphocyte Count \\<180/mm3 and/or cluster of differentiation 4 (CD4) Count \\<50/mm3\n\nKey Exclusion Criteria:\n\n* History of AdV, BKV, CMV, EBV, HHV-6, and/or JCV end-organ disease within 6 months prior to randomization\n* Evidence of active Grade \\>2 acute GVHD\n* Presence of non-minor uncontrolled or progressive bacterial, viral or fungal infections\n* Known history or current (suspected) diagnosis of CRS requiring treatment associated with the administration of peptides, proteins, and/or antibodies\n* Ongoing therapy with high-dose systemic corticosteroids (ie, prednisone equivalent dose \\>0.5 mg/kg/day) within 24 hours prior to dosing\n* Relapse of primary malignancy other than minimal residual disease\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Experiencing Clinically Significant Infections or Episodes of End-organ Disease","description":"The number of participants experiencing clinically significant infections or episodes of end-organ disease due to AdV, BKV, CMV, EBV, HHV-6, or JCV through Week 14","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Clinically Significant Infections or Episodes of End-organ Disease","description":"The number of participants experiencing clinically significant infections or episodes of end-organ disease due to AdV, BKV, CMV, EBV, HHV-6, or JCV through Week 26.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Clinically Significant Infections or Episodes of End-organ Disease Due to Adenovirus (AdV)","description":"The number of participants experiencing clinically significant infections or episodes of end-organ disease due to AdV, BKV, CMV, EBV, HHV-6, or JCV from each individual virus through Week 26 (6 endpoints each at Week 26).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Clinically Significant Infections or Episodes of End-organ Disease Due to BKV","description":"The number of participants experiencing clinically significant infections or episodes of end-organ disease due to AdV, BKV, CMV, EBV, HHV-6, or JCV from each individual virus through Week 14 and Week 26 (6 endpoints each at Week 14 and Week 26).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Clinically Significant Infections or Episodes of End-organ Disease Due to Cytomegalovirus (CMV)","description":"The number of participants experiencing clinically significant infections or episodes of end-organ disease due to AdV, BKV, CMV, EBV, HHV-6, or JCV from each individual virus through Week 26 (6 endpoints each at Week 26).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Clinically Significant Infections or Episodes of End-organ Disease Due to Epstein-Barr Virus (EBV)","description":"The number of participants experiencing clinically significant infections or episodes of end-organ disease due to AdV, BKV, CMV, EBV, HHV-6, or JCV from each individual virus through Week 26 (6 endpoints each at Week 26).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Clinically Significant Infections or Episodes of End-organ Disease Due to Human Herpes Virus 6 (HHV-6)","description":"The number of participants experiencing clinically significant infections or episodes of end-organ disease due to AdV, BKV, CMV, EBV, HHV-6, or JCV from each individual virus through Week 26 (6 endpoints each at Week 26).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Clinically Significant Infections or Episodes of End-organ Disease Due to John Cunningham Virus (JCV)","description":"The number of participants experiencing clinically significant infections or episodes of end-organ disease due to AdV, BKV, CMV, EBV, HHV-6, or JCV from each individual virus through Week 26 (6 endpoints each at Week 26).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Rates of Overall and Non-Relapse Mortality","description":"The number of mortality events due to non-relapse causes through Week 52.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":19,"n":26},"commonTop":["Diarrhoea","Acute graft versus host disease in skin","Abdominal Pain","Weight decreased","Pain in extremity"]}}}